The World Health Organization announced a significant advancement in the global fight against HIV by recommending injectable prevention treatments over daily pills.
This shift in delivery methods matters because it removes the burden of daily adherence, potentially increasing the number of people who can effectively protect themselves from infection through pre-exposure prophylaxis, known as PrEP.
PrEP consists of medications that reduce the probability of contracting HIV through sexual contact or injection drug use, according to Prensa.com [1]. Traditional PrEP involves daily oral pills containing antiretroviral drugs. These medications maintain protective levels of the drug in the body to lower the chance of infection when taken consistently [1, 4]. In some cases, the treatment has been simplified by combining two drugs into a single daily pill [4].
However, the transition toward long-acting injectables is gaining momentum. The World Health Organization said the new injectable option helps prevent transmission by moving away from the need for daily tablets [2].
Implementation of these new methods varies by region. Spain has become the first European country to finance the injectable treatment, which is administered every two months in that country [2]. Other regulatory guidelines have approved a biannual schedule, requiring the injection twice a year [3]. Some early phase one study data suggested a frequency of once per year, though this differs from the current approved regulatory schedules [2].
Health authorities in countries such as Panama continue to provide access to PrEP to reduce infection rates [1]. The move toward injectables is designed to address the challenges of consistency associated with oral medication. By reducing the frequency of doses, health organizations aim to close gaps in prevention coverage for high-risk populations [2, 3].
“The World Health Organization, OMS, dio a conocer un importante avance en la lucha mundial contra el VIH”
The transition from daily oral PrEP to long-acting injectables represents a shift toward patient-centric prevention. By reducing the dosing frequency from 365 days a year to as few as two or six doses, health authorities are attempting to eliminate pill fatigue and the stigma associated with daily medication, which often hinders the effectiveness of HIV prevention programs in marginalized communities.
